KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of KMC SPECIALITY HOSPITALS (INDIA) LTD. stock ₹126, price ₹163, that is 22.8% below the price, quality 76 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ₹35.45 – ₹183.30 · fair‑value band ₹82.10 – ₹168.68 · the ₹163.35 price screens above the ₹126.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow KMC SPECIALITY HOSPITALS (INDIA) in your weekly email
Every Wednesday you see whether KMC SPECIALITY HOSPITALS (INDIA) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL) currently trades at ₹163.35, while our model-based Fair Value estimate is ₹126.08, 23% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹97.73 per share, and 0 of the 24 models we run sit above the ₹163.35 price.
Bear case: the Economic Profit group reads lowest at ₹24.13, and 24 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹82.10 (bear) to ₹168.68 (bull), the price of ₹163.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Health Care sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
KMC SPECIALITY HOSPITALS (INDIA) LTD. reported revenue of ₹3.1B in FY2026 versus ₹1.4B in FY2022, a compound +22.6%/yr. Reported net income was ₹467M in FY2026, compounding +18.5%/yr from FY2022.
Key figures
Market cap ₹26.6B (≈ $284M) Micro · P/E ratio 48.3 · P/S ratio 8.05 · EPS (TTM) ₹3.38 · Net margin 16.9% · Return on equity 24.9% · Return on assets (EBIT) 18.2% (5-year average) · Operating margin 24.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 79 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 136% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −55% fair-value upside, at −23%, KMCSHIL screens cheaper than that median.
Fair Value models
Bear₹82.10Fair Value ₹126.08Bull₹168.68
Price ₹163.35 · Downside -22.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹2.07 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+32.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.6%
Start year 2021 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+18.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+18.5%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 22%
2026 sits 75% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+38.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +32.9% a year for the price.
Compare KMC SPECIALITY HOSPITALS (INDIA) LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Hospitals” was too small, so the broader sector is used.)Health Care · 2276 stocks
Beats the sector median on 6/13 measures
A mixed picture versus its sector peers.
Valuation
Quality Score76 · Top 25%
Fair Value upside−22.8% · Below median
Profitability
Return on equity (12 months)24.9% · Top 25%
Return on assets14.1% · Top 25%
Net margin (12 months)16.9% · Top 25%
Operating margin (12 months)24.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)37.9% · Top 25%
Balance sheet
Debt / equity0.29× · Above median
Valuation Multiplesvs Health Care median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ₹126.08 versus a price of ₹163.35, about 23% lower (overvalued).
What is the fair value of KMCSHIL?
Our model-based fair value for KMC SPECIALITY HOSPITALS (INDIA) LTD. is ₹126.08 (as of Nov 8, 2026), built from audited fundamentals. The current price: ₹163.35.
What is the quality score of KMCSHIL?
KMC SPECIALITY HOSPITALS (INDIA) LTD. has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
Our model-based price target is the fair value of ₹126.08 (as of Nov 8, 2026) from 24 valuation models. Cautious scenario ₹82.10, optimistic scenario ₹168.68. It is a calculation from audited fundamentals, not an analyst target.
What is the KMC SPECIALITY HOSPITALS (INDIA) LTD. stock forecast for 2026?
Our models put fair value at ₹126.08, about 23% lower versus a price of ₹163.35 (overvalued). Cautious scenario ₹82.10, optimistic scenario ₹168.68. The calculation is refreshed regularly with new filings.
What is the revenue of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
KMC SPECIALITY HOSPITALS (INDIA) LTD. reported trailing-twelve-month revenue of about ₹3.3B (latest available figure, as of Nov 8, 2026).
What growth is priced into KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
For today's price to be fair in a discounted-cash-flow model, KMC SPECIALITY HOSPITALS (INDIA) LTD. would have to grow free cash flow by +38.4 % per year for five years (discount rate 15.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +24.6 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of KMCSHIL use?
Our models discount KMC SPECIALITY HOSPITALS (INDIA) LTD. at 15.4 %: a base by market capitalisation (micro), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For KMC SPECIALITY HOSPITALS (INDIA) LTD. that is +38.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (15.4 %) and the same formula as our fair value.
How much growth has KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL) delivered so far?
Over the past 5 years revenue at KMC SPECIALITY HOSPITALS (INDIA) LTD. grew +24.6 % a year. The price currently implies free-cash-flow growth of +38.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The free-cash-flow yield on the price is 2.34 %: that much free cash flow KMC SPECIALITY HOSPITALS (INDIA) LTD. produces per unit of market value. When it exceeds the discount rate of our models (15.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For KMC SPECIALITY HOSPITALS (INDIA) LTD. it is ₹126.08 per share (as of Nov 8, 2026), against a price of ₹163.35. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is KMC SPECIALITY HOSPITALS (INDIA) LTD. stock overvalued or undervalued in 2026?
As of Nov 8, 2026, KMCSHIL trades above its calculated fair value: price ₹163.35, fair value ₹126.08, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KMCSHIL?
No. The price is what the market pays today (₹163.35); the fair value is what the company's own numbers justify (₹126.08). For KMC SPECIALITY HOSPITALS (INDIA) LTD. the two are ₹37.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is KMC SPECIALITY HOSPITALS (INDIA) LTD. worth?
The market values KMC SPECIALITY HOSPITALS (INDIA) LTD. at about ₹26.6B (market capitalisation, as of Nov 8, 2026). Per share that is ₹163.35; our models calculate a fair value of ₹126.08 per share.
What do the bullish and bearish scenarios say about KMCSHIL?
Our models span a range for KMC SPECIALITY HOSPITALS (INDIA) LTD.: cautious scenario ₹82.10, base ₹126.08, optimistic ₹168.68 per share (as of Nov 8, 2026, price ₹163.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of KMCSHIL?
KMC SPECIALITY HOSPITALS (INDIA) LTD. trades at a price-to-earnings ratio of 48.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹126.08 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2019 to 2026), reported earnings: 32.2. Other multiples: P/B 12.7, P/S 8.0, EV/EBITDA 26.7.
How solid is the balance sheet of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
Balance-sheet figures for KMC SPECIALITY HOSPITALS (INDIA) LTD. (as of Nov 8, 2026): return on equity 24.9%, debt of 0.29 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is KMCSHIL from its 52-week high?
KMC SPECIALITY HOSPITALS (INDIA) LTD. trades at ₹163.35, about 11% below its 52-week high of ₹183.30 and 136% above the low of ₹69.19 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹126.08 is for.
Which stocks are comparable to KMC SPECIALITY HOSPITALS (INDIA) LTD.?
From the same area (Health Care) we also value 516110, PINC, SHUKRAPHAR, TITANBIO, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is KMC SPECIALITY HOSPITALS (INDIA) LTD. stock attractive at the current price?
The data as of Nov 8, 2026: price ₹163.35, calculated fair value ₹126.08 (−23%), Quality Score 76/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KMCSHIL calculated?
We run KMC SPECIALITY HOSPITALS (INDIA) LTD. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹126.08 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. KMC SPECIALITY HOSPITALS (INDIA) LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The closing price on Nov 6, 2026 was ₹163.35. Our model-based fair value is ₹126.08, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with KMC SPECIALITY HOSPITALS (INDIA) LTD. right now?
A high-quality business (quality 76/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range (₹82.10 to ₹168.68) leaves room in how you read the outcome.
Key figures of KMC SPECIALITY HOSPITALS (INDIA) LTD.
How large is the market capitalisation of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The market capitalisation of KMC SPECIALITY HOSPITALS (INDIA) LTD. is ₹26.6B (≈ $284M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The price-to-sales ratio of KMC SPECIALITY HOSPITALS (INDIA) LTD. is 8.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
Earnings per share at KMC SPECIALITY HOSPITALS (INDIA) LTD. are ₹3.38 (price ÷ EPS = P/E 48.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The net margin of KMC SPECIALITY HOSPITALS (INDIA) LTD. is 16.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The return on equity (ROE) of KMC SPECIALITY HOSPITALS (INDIA) LTD. is 24.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
On an EBIT basis the return on assets of KMC SPECIALITY HOSPITALS (INDIA) LTD. is 18.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
The operating margin of KMC SPECIALITY HOSPITALS (INDIA) LTD. is 24.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
Revenue at KMC SPECIALITY HOSPITALS (INDIA) LTD. is growing +37.9% versus a year earlier (3y avg +25.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL)?
Earnings per share at KMC SPECIALITY HOSPITALS (INDIA) LTD. are growing +122% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does KMC SPECIALITY HOSPITALS (INDIA) LTD. (KMCSHIL) carry?
The net debt of KMC SPECIALITY HOSPITALS (INDIA) LTD. is ₹210M (fiscal year 2026, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch KMC SPECIALITY HOSPITALS (INDIA) LTD. in the live analysis
One click puts KMC SPECIALITY HOSPITALS (INDIA) LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 8, 2026